Friday 6 November 2026
Export SYRE’s income statement to Excel — free account
Spyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
104.18
7.59
+7.86%
Follow SYRE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
26.70 | 18.09 | 8.71 | 12.89 | |
Current Ratio |
27.40 | 18.53 | 8.97 | 13.25 | |
Net Debt/EBITDA |
10.14 | 27.51 | 16.25 | 13.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 2.26 | 0.99 | 0.71 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.88) | (0.82) | (0.73) | (0.70) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.88) | (0.82) | (0.73) | (0.70) | |
Cash per Share |
12.12 | 13.52 | 9.44 | 11.81 | |
Shareholders Equity per Share |
11.89 | 13.00 | 8.54 | 11.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.89 | 13.00 | 8.54 | 11.17 | |
Free Cash Flow |
(77.49) | (69.88) | (57.37) | (44.58) | |
Working Capital |
1,059.59 | 1,109.70 | 678.79 | 719.10 | |
Net Current Asset Value |
1,051.54 | 1,101.14 | 670.81 | 715.24 | |
| Other line items | |||||
Average Payables |
8.46 | 4.72 | 4.69 | 4.79 | |
Average Assets |
802.17 | 855.92 | 666.87 | 693.13 | |
Average Common Equity |
602.20 | 627.33 | 420.89 | 460.70 |
Columns are period end dates · fundamentals updated 5 Nov 2026